Cross-Market Price Comparison
| Other Listed Market | Shenzhen (SZSE) — 康龙化成 |
|---|---|
| Other Market Stock Code | 300759 |
| H-Share Offer Price | To be extracted |
| Other Market Price | Loading... |
| Reference Exchange Rate | Loading... |
| H-Share Offer Price Premium/Discount vs Other Market | Loading... |
Company Overview
| Stock Name | Pharmaron |
|---|---|
| Stock Code | 03759 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 領先的全流程一體化醫藥研發服務平台,提供藥物發現、臨床前及早期臨床開發服務,並拓展下游臨床後期開發及商業化生產等服務。 |
| Listing Date | 2019-11-28 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國北京經濟技術開發區泰河路6號1幢8層 |
| Business Address (Hong Kong) | 香港灣仔皇后大道東248號陽光中心40樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | pharmaron.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | Yes (A股) |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 39.50 / shares |
| Offer Price Range | To be extracted |
| Lot Size | 100 shares |
| Entry Threshold | To be extracted |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2019-11-14 to 2019-11-20 |
| Global Offering Shares | 116,536,100 shares |
| HK Public Offer Shares (Initial) | 11,653,700 shares (10.0%) |
| Public Offer Lots (Initial) | 116,537lots (Pool A58,268lots,Pool B58,269lots) |
| International Placing Shares (Initial) | 104,882,400 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 776,907,062 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 27.2% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 4,603,175,950 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 100 | HK$ 3,950 |
| 2 lots | 200 | HK$ 7,900 |
| 3 lots | 300 | HK$ 11,850 |
| 4 lots | 400 | HK$ 15,800 |
| 5 lots | 500 | HK$ 19,750 |
| 6 lots | 600 | HK$ 23,700 |
| 7 lots | 700 | HK$ 27,650 |
| 8 lots | 800 | HK$ 31,600 |
| 9 lots | 900 | HK$ 35,550 |
| 10 lots | 1,000 | HK$ 39,500 |
| 15 lots | 1,500 | HK$ 59,250 |
| 20 lots | 2,000 | HK$ 79,000 |
| 25 lots | 2,500 | HK$ 98,750 |
| 30 lots | 3,000 | HK$ 118,500 |
| 35 lots | 3,500 | HK$ 138,250 |
| 40 lots | 4,000 | HK$ 158,000 |
| 45 lots | 4,500 | HK$ 177,750 |
| 50 lots | 5,000 | HK$ 197,500 |
| 60 lots | 6,000 | HK$ 237,000 |
| 70 lots | 7,000 | HK$ 276,500 |
| 80 lots | 8,000 | HK$ 316,000 |
| 90 lots | 9,000 | HK$ 355,500 |
| 100 lots | 10,000 | HK$ 395,000 |
| 200 lots | 20,000 | HK$ 790,000 |
| 300 lots | 30,000 | HK$ 1,185,000 |
| 400 lots | 40,000 | HK$ 1,580,000 |
| 500 lots | 50,000 | HK$ 1,975,000 |
| 600 lots | 60,000 | HK$ 2,370,000 |
| 700 lots | 70,000 | HK$ 2,765,000 |
| 800 lots | 80,000 | HK$ 3,160,000 |
| 900 lots | 90,000 | HK$ 3,555,000 |
| 1,000 lots | 100,000 | HK$ 3,950,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 2,000 lots | 200,000 | HK$ 7,900,000 |
| 3,000 lots | 300,000 | HK$ 11,850,000 |
| 4,000 lots | 400,000 | HK$ 15,800,000 |
| 5,000 lots | 500,000 | HK$ 19,750,000 |
| 6,000 lots | 600,000 | HK$ 23,700,000 |
| 7,000 lots | 700,000 | HK$ 27,650,000 |
| 8,000 lots | 800,000 | HK$ 31,600,000 |
| 9,000 lots | 900,000 | HK$ 35,550,000 |
| 10,000 lots | 1,000,000 | HK$ 39,500,000 |
| 20,000 lots | 2,000,000 | HK$ 79,000,000 |
| 30,000 lots | 3,000,000 | HK$ 118,500,000 |
| 40,000 lots | 4,000,000 | HK$ 158,000,000 |
| 50,000 lots | 5,000,000 | HK$ 197,500,000 |
| 58,268 lots | 5,826,800 | HK$ 230,158,600 |
Stock Connect Inclusion Analysis
| HK Market Cap | HK$ 8.51B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利约人民币335.8百万元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2016 | 2017 | 2018 | 2019-06 |
|---|---|---|---|---|
| Revenue | 1,634,239 | 2,294,118 | 2,908,123 | 1,636,513 |
| Cost of sales | -1,136,333 | -1,519,653 | -1,960,073 | -1,114,088 |
| Gross profit | 497,906 | 774,465 | 948,050 | 522,425 |
| Other income and gains, net | 39,034 | 16,164 | 53,759 | 21,263 |
| Selling and distribution expenses | -32,038 | -47,163 | -54,647 | -28,766 |
| Administrative expenses | -252,328 | -345,773 | -420,456 | -241,463 |
| Operating profit | 229,931 | 336,983 | 479,442 | 234,890 |
| Net finance costs | -21,377 | -68,536 | -82,366 | -42,399 |
| Share of associates and JVs | 0 | 0 | -1,132 | -5,798 |
| Profit before tax | 208,554 | 268,447 | 395,944 | 186,693 |
| Income tax expense | -37,220 | -49,783 | -60,101 | -30,012 |
| Profit for the year | 171,334 | 218,664 | 335,843 | 156,681 |
| Profit attributable to owners | 171,334 | 222,497 | 336,042 | 161,323 |
Balance Sheet
| Item | 2016 | 2017 | 2018 | 2019-06 |
|---|---|---|---|---|
| Cash and cash equivalents | 461,944 | 293,601 | 307,235 | 331,324 |
| Trade and bills receivables | 352,048 | 494,897 | 603,993 | 654,058 |
| Inventories | 42,847 | 59,015 | 70,148 | 81,186 |
| Total current assets | 1,092,744 | 1,070,843 | 1,276,107 | 1,604,706 |
| Total assets | 2,912,771 | 4,143,664 | 4,802,079 | 5,347,325 |
| Total current liabilities | 678,098 | 980,654 | 1,308,048 | 1,436,762 |
| Total liabilities | 1,153,146 | 2,145,560 | 2,475,508 | 2,431,069 |
| Total equity | 1,759,625 | 1,998,104 | 2,326,571 | 2,916,256 |
| Equity attributable to owners | 1,759,625 | 1,985,486 | 2,313,580 | 2,833,898 |
| Interest-bearing borrowings | 668,476 | 1,356,662 | 1,433,967 | 1,330,514 |
Cash Flow Statement
| Item | 2016 | 2017 | 2018 | 2019-06 |
|---|---|---|---|---|
| Net cash from operating activities | 260,460 | 594,138 | 790,744 | 252,315 |
| Net cash from investing activities | -1,139,082 | -1,279,911 | -714,599 | -502,067 |
| Net cash from financing activities | 1,256,275 | 530,314 | -69,046 | 278,194 |
| Net increase in cash | 377,653 | -155,459 | 7,099 | 28,442 |
| Depreciation of PP&E | 124,464 | 186,171 | 255,192 | 148,216 |
| Depreciation of right-of-use assets | 24,928 | 44,246 | 58,027 | 29,717 |
| Amortisation of intangible assets | 708 | 2,248 | 1,889 | 1,378 |
| Purchase of PP&E | -962,058 | -874,100 | -523,609 | -303,386 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 42.25 |
|---|---|
| First Day Open | HK$ 43.45 |
| First Day Change | 6.96% |
| First Day Volume | 51976500.0 |
| First Day Turnover | 2226200000.0 |
| Use of Proceeds | 1、約1,303.3百萬港元(或所得款項凈額約30%)將用于擴展中國實驗室及生產設施的產能及能力;
2、約434.4百萬港元(或所得款項凈額約10%)撥付美國及英國業務的進一步擴張;
3、約868.8百萬港元(或所得款項凈額約20%)將用于建立有關研發生物制劑的醫藥研發服務平臺;
4、約651.6百萬港元(或所得款項凈額約15%)將用于擴展臨床開發服務實力及能力;
5、約651.6百萬港元(或所得款項凈額約15%)將用于透過潛在收購在美國、歐洲、日本或中國提供醫藥研發服務且擁有尖端研發技術的合同研發服務及合同生產服務公司及/或其業務,來擴展我們的產能及/或能力;
6、約434.4百萬港元(或所得款項凈額約10%)將用于一般企業用途及用作營運資金。 |
Underwriting Syndicate
Joint Sponsors (3)
Overall Coordinators (3)
Joint Bookrunners (4)
Joint Lead Managers (3)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Athos Asia Event Driven Master Fund | 195,809,400 HKD | — | 4.25% | — | 6 months | 2020-05-28 |
| 2 | Lake Bleu Prime Healthcare Master Fund Limited | 313,298,200 HKD | — | 6.81% | — | 6 months | 2020-05-28 |
| 3 | Oaktree Funds | 195,809,400 HKD | — | 4.25% | — | 6 months | 2020-05-28 |
| 4 | OrbiMed Funds | 234,973,650 HKD | — | 5.10% | — | 6 months | 2020-05-28 |
| 5 | 中国国有企业结构调整基金股份有限公司 | 313,298,200 HKD | — | 6.81% | — | 6 months | 2020-05-28 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 樓柏良 | — |
| Company Secretary | 麥寶文 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 樓博士、樓先生及鄭女士為一致行動人士,於全球發售前合共持有約28.56% A股;中信証券透過受控法團持有約28.29% A股;君聯資本系持股約18.49% A股。 |
|---|




